Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
PSTV

PSTV - Plus Therapeutics Inc Stock Price, Fair Value and News

$0.25+0.01 (+4.17%)
Market Closed

10/100

PSTV

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

10/100

PSTV

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$0.22

Target 3M

$0.24

Target 6M

$0.23

PSTV Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PSTV Price Action

Last 7 days

-13.8%

Last 30 days

-54.5%

Last 90 days

-52.8%

Trailing 12 Months

-79.0%

PSTV RSI Chart

PSTV Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PSTV Valuation

Market Cap

34.4M

Price/Earnings (Trailing)

-1.67

Price/Sales (Trailing)

6.53

Price/Free Cashflow

-2.17

PSTV Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$0.22

Target 3M

$0.24

Target 6M

$0.23

PSTV Fundamentals

PSTV Revenue

Revenue (TTM)

5.3M

Rev. Growth (Yr)

-4.05%

Rev. Growth (Qtr)

0.5%

PSTV Earnings

Earnings (TTM)

-20.6M

Earnings Growth (Yr)

-53.9%

Earnings Growth (Qtr)

-185.87%

PSTV Profitability

Return on Equity

-407.12%

Return on Assets

-110.21%

Free Cashflow Yield

-46%

PSTV Investor Care

Shares Dilution (1Y)

2230.75%

Diluted EPS (TTM)

-1.83

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20255.2M5.3M5.3M0
20245.1M5.4M5.6M5.8M
20230000
20220000
20210000
2020000303.0K
20192.8M02.4M3.2M
20183.6M4.0M3.1M3.0M
20176.2M5.0M4.4M3.7M
20166.7M6.6M6.7M6.7M
20154.8M5.7M6.9M6.0M
20146.0M6.1M5.0M5.0M
20139.6M8.5M8.8M7.3M
20128.1M7.6M6.8M8.7M
20116.8M7.1M8.3M8.0M
201008.5M8.1M7.7M
20090008.9M
Get all data in R, Python etc through our Historical Stock Data APIs

About Plus Therapeutics Inc

PSTV
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
 CEO
 WEBSITEhttps://plustherapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES17

Plus Therapeutics Inc Frequently Asked Questions

PSTV is the stock ticker symbol of Plus Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Plus Therapeutics Inc is 34.36 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check PSTV's fair value in chart for subscribers.

The fair value guage provides a quick view whether PSTV is over valued or under valued. Whether Plus Therapeutics Inc is cheap or expensive depends on the assumptions which impact Plus Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PSTV.

As of Wed Jan 28 2026, PSTV's PE ratio (Price to Earnings) is -1.67 and Price to Sales (PS) ratio is 6.53. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PSTV PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Plus Therapeutics Inc has provided -0.679 (multiply by 100 for percentage) rate of return.